Accessibility Menu
Genenta Science S.p.A. logo

Genenta Science S.p.A.(NASDAQ) GNTA

Market Cap$30.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-88%
5 YearN/A
1 Year-66%
1 Month-19%
$1.33
+0.00%
+0.00Today
After hours$1.30-$0.03 (-2.26%)
Genenta Science S.p.A. last closing stock price
MetricPriceDate
Last closeUSD 1.312026-08-06
Genenta Science S.p.A. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.25%USD 1.512026-07-30
1 month-18.63%USD 1.612026-07-07
3 month+109.23%USD 0.632026-05-08
Year to date-12.08%USD 1.492025-12-31
1 year-65.53%USD 3.802025-08-06
3 year-78.31%USD 6.042023-08-07
Since inception-88.09%USD 11.002021-12-15

Genenta Science S.p.A. Financials at a Glance

Market Cap

$30.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€0.00

Net Income (TTM)

-€15.41M

EPS (TTM)

-$0.37

P/E Ratio

-3.53

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.33

Volume

21,155

Open

$1.33

Previous Close

$1.31

Daily Range

$1.30 - $1.35

52-Week Range

$0.55 - $10.00

Estimated Earnings Date

Sep 2, 2026

GNTA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genenta Science S.p.A.

Genenta Science S.p.A. is a biotechnology company focused on developing innovative cell and gene therapies for cancer treatment. The company leverages its proprietary platform to deliver therapeutic agents directly to tumor sites, which may enhance efficacy and reduce systemic side effects. Led by experienced professionals, Genenta is advancing a pipeline of novel therapies while exploring strategic partnerships. This approach aims to establish the company as a leader in gene-based cancer therapies.

Products and Services

Tesetaxel: An oral taxane for various cancers, including gastric and breast cancer.

Ganite: An intravenous formulation for treating cancer-related hypercalcemia.

Oral gallium compounds: Under development for skeletal diseases and other uses.

What Makes Genenta Science S.p.A. Special

Genenta stands out due to its proprietary technology platform that uses genetically modified stem cells to target tumors effectively. This potentially increases the therapeutic impact while minimizing systemic toxicity, differentiating it from traditional therapies.

Five Things You Need to Know

Genenta focuses primarily on oncology, developing therapies for cancer treatment.

The company is advancing tesetaxel, an oral taxane, through various clinical trials.

Fast Track and Orphan Drug designations were granted to tesetaxel, facilitating its development.

The company's strategy includes forming strategic partnerships to optimize its technology.

Genenta's leadership team brings deep expertise in gene therapy and oncology.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Employees

9

CEO

Pierluigi Paracchi

Headquarters

Milan, MI 20132, IT

GNTA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-36.82%

Return on Capital

-21.54%

Return on Assets

-19.60%

Earnings Yield

-28.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$30.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

23.43M

Volume

21.16K

Avg. Volume

1.46M

Financials (TTM)

Gross Profit

-€72.73K

Operating Income

-€16.39M

EBITDA

-€14.97M

Operating Cash Flow

-€13.95M

Capital Expenditure

-€15.29K

Free Cash Flow

-€13.97M

Cash & ST Invst.

€28.15M

Total Debt

€7.60M

Genenta Science S.p.A. Performance Analysis

Genenta Science S.p.A. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 0N/A
20242024-12-31EUR 0N/A
20252025-12-31EUR 0N/A
Genenta Science S.p.A. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Genenta Science S.p.A. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.4936.3%
20232023-12-31EUR -0.6941.3%
20242024-12-31EUR -0.53-23.7%
20252025-12-31EUR -0.37-29.1%
Genenta Science S.p.A. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3018.5%
Q42024-12-31-22.7%
Q22025-06-3025.9%
Q42025-12-3135.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€0.00

N/A

Gross Profit

-€14.04K

+33.0%

Gross Margin

0.00%

N/A

Market Cap

$30.70MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.41M

N/A

Employees

9

N/A

Net Income

-€2.68M

+44.1%

EBITDA

-€2.66M

+44.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€28.15M

+49.9%

Total Debt

€7.60M

N/A

Accounts Receivable

€1.29M

-35.8%

Inventory

€0.00

N/A

Long Term Debt

€7.60M

N/A

Short Term Debt

€0.00

N/A

Return on Assets

-19.60%

N/A

Return on Invested Capital

-21.33%

N/A

Free Cash Flow

-€1.69M

-46535.6%

Operating Cash Flow

-€1.69M

-46548.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BRNSBarinthus Biotherapeutics plc
$0.57-0.89%
TELOTelomir Pharmaceuticals, Inc. Common Stock
$1.17-0.85%
SKYESkye Bioscience, Inc.
$0.47-16.02%
INMBINmune Bio, Inc.
$1.91+0.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
TTDThe Trade Desk
$17.67-0.07%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$26.93-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$72.03-0.01%
SPCXSpace Exploration Technologies
$114.92+0.06%

Questions About GNTA

What is the current price of Genenta Science S.p.A.?

Genenta Science S.p.A. is trading at $1.31 per share.

What is the 52-week range for Genenta Science S.p.A.?

Over the past 52 weeks, Genenta Science S.p.A. has traded between $0.55 and $10.00.

How much debt does Genenta Science S.p.A. have?

As of the most recent reporting period, Genenta Science S.p.A. reported total debt of €8.93M.

How much cash does Genenta Science S.p.A. have on hand?

Genenta Science S.p.A. reported €6.49M in cash and cash equivalents in its most recent financial results.

What is Genenta Science S.p.A.’s dividend yield?

Genenta Science S.p.A. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.